This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2a (PREX2A; DEPDC2A)	Studies in cell culture suggest that inhibiting PREX2A signaling could help treat cancer. In human breast cancer cell lines, small hairpin RNA-mediated knockdown of PREX2A reduced cell proliferation compared with that seen using a control shRNA. Next steps could include developing compounds to inhibit PREX2A activity.	Patent and licensing status unavailable	Fine, B. <i>et al. Science</i> ; published online Sept. 3, 2009; doi:10.1126/science.1173569 Contact: Ramon Parsons, Columbia University, New York, N.Y. e-mail: rep15@columbia.edu
<i>SciBX</i> 2(36); doi:10.1038/scibx.2009.1374 Published online Sept. 17, 2009				